Business context and reporting period
The supplied filing is Quintiles Transnational Holdings Inc.’s Form 10-K for the fiscal year ended December 31, 2015, not a filing under the name IQVIA Holdings Inc. The company provided biopharmaceutical development and commercial outsourcing services through Product Development and Integrated Healthcare Services, operated in approximately 100 countries, and had about 36,100 employees. The filing also reports unaudited fourth-quarter results.
Financial results and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Service revenue | $4.326 billion | $4.166 billion |
| Total revenue, including reimbursed expenses | $5.738 billion | $5.460 billion |
| Operating income | $646.6 million | $590.4 million |
| Net income attributable to shareholders | $387.2 million | $356.4 million |
| Diluted EPS | $3.08 | $2.72 |
| Cash from operations | $475.7 million | $431.8 million |
| Capital expenditures | $78.4 million | $82.7 million |
| Cash and cash equivalents at year-end | $977.2 million | $867.4 million |
| Total debt and capital leases | $2.501 billion | $2.306 billion |
Service revenue grew 3.9% as reported and 9.0% at constant currency; foreign exchange reduced reported growth by about $212 million. Operating margin was approximately 15.0% of service revenue, compared with 14.2% in 2014. The effective tax rate was 29.5%. Current assets were $2.412 billion and current liabilities $1.594 billion at year-end. Cash held in the United States was $244.9 million. Approximate net debt, calculated as reported debt less cash, was $1.52 billion.
Product Development generated $3.192 billion of service revenue and a 22.4% segment operating margin. Integrated Healthcare Services generated $1.135 billion and a 7.4% margin. The company reported $12.038 billion of backlog, up 7% from 2014; $8.188 billion was not expected to convert to revenue in 2016. Net new business fell 5.1% to $5.319 billion.
In Q4 2015, service revenue was $1.129 billion, operating income $178.0 million, net income attributable to shareholders $104.6 million, and diluted EPS $0.85. In Q4 2014, the corresponding figures were $1.064 billion, $158.9 million, $88.4 million, and $0.69.
Material changes versus prior comparable period
- Constant-currency service revenue growth was positive, but currency headwinds materially reduced reported growth.
- Both segments expanded operating margins. Product Development’s margin rose from 20.8% to 22.4%; Integrated Healthcare Services’ rose from 6.1% to 7.4%.
- Operating cash flow increased by $43.9 million. Management cited higher earnings and payables, partly offset by increased cash use from receivables and a seven-day increase in days sales outstanding.
- Net new business declined from $5.602 billion. Product Development signings fell 5.8%, partly because 2014 included renewals of two five-year contracts; Integrated Healthcare Services signings fell 2.5%.
- Debt increased following the May 2015 refinancing. The company issued $800 million of 4.875% notes due 2023 and established new term loans and a $500 million revolving facility.
Outlook, management commentary, risks, and unusual items
The filing does not provide specific company revenue or earnings guidance. Management estimated that outsourced clinical development services could grow 6%–8% annually from 2015 through 2018 and expressed a similar market-growth expectation for Integrated Healthcare Services. These are industry estimates, not company forecasts. Management stated that cash, expected operating cash flow, and available facilities should fund operations, capital expenditures, and debt obligations for at least 12 months.
- A February 2016 restructuring plan was expected to cost approximately $22 million and, if implemented, reduce 2016 service revenue by approximately $18 million–$20 million versus 2015. Separate 2015 restructuring plans were expected to generate $50 million–$60 million in annualized savings.
- 2015 included $30.8 million of restructuring charges, a $2.5 million impairment for a Japan facility, and a $7.8 million debt-extinguishment loss. A $16.9 million release of deferred revenue followed the early closeout of a customer arrangement.
- The Q 2 Solutions joint venture with Quest Diagnostics closed in July 2015. Quintiles retained 60% control and consolidated the business; Quest owns 40%. The transaction increased goodwill and introduced a material noncontrolling interest.
- Key risks include customer project cancellations or delays, backlog conversion uncertainty, pricing and cost overruns, foreign exchange exposure, privacy and cybersecurity incidents, regulatory noncompliance, competition, and reliance on skilled staff. About 32% of service revenue was denominated in non-U.S. currencies.
- Debt-related risks include variable interest exposure and restrictive covenants. The maximum total leverage covenant was 5.75 to 1.00; the company reported compliance at year-end. Some $534 million of revolving borrowing capacity was available across facilities.
- Legal proceedings were described as incidental to the business; management did not believe their resolution was reasonably likely to materially affect the financial statements. The independent auditor gave an unqualified opinion and reported effective internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity and period: the supplied document is Quintiles Transnational Holdings Inc.’s 2015 10-K, not an IQVIA-named filing.
- Assess whether backlog and new business convert to revenue as expected, given cancellations, delays, long project timelines, and the large portion scheduled beyond 2016.
- Track constant-currency growth separately from reported growth and monitor the impact of foreign exchange on revenue, margins, and cash.
- Review debt maturities, refinancing terms, covenant headroom, variable-rate exposure, and the limits on upstreaming foreign cash or paying dividends.
- Evaluate Q 2 Solutions integration and returns, the planned restructuring costs and savings, and the Encore reporting unit’s performance; management noted that weaker-than-expected initiatives could prompt additional goodwill impairment analysis.
- Monitor receivables and days sales outstanding, customer contract changes, and the subsequent restructuring’s stated revenue impact.